The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
Richard G. Gray
No relevant relationships to disclose
Daniel Rea
No relevant relationships to disclose
Kelly Handley
No relevant relationships to disclose
Sarah Jane Bowden
No relevant relationships to disclose
Philip Perry
No relevant relationships to disclose
Helena Margaret Earl
No relevant relationships to disclose
Christopher John Poole
No relevant relationships to disclose
Tom Bates
No relevant relationships to disclose
Shan Chetiyawardana
No relevant relationships to disclose
John A. Dewar
No relevant relationships to disclose
Indrajit Nalinika Fernando
No relevant relationships to disclose
Robert Grieve
No relevant relationships to disclose
Jonathan Nicoll
No relevant relationships to disclose
Zenor Rayter
No relevant relationships to disclose
Anne Robinson
No relevant relationships to disclose
Asad Salman
No relevant relationships to disclose
John Yarnold
No relevant relationships to disclose
Sarah Bathers
No relevant relationships to disclose
Andrea Marshall
No relevant relationships to disclose
Martin Lee
No relevant relationships to disclose